<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230737</url>
  </required_header>
  <id_info>
    <org_study_id>R01AT001521-01A1</org_study_id>
    <secondary_id>R01AT001521-01A1</secondary_id>
    <nct_id>NCT00230737</nct_id>
  </id_info>
  <brief_title>Effects of Melatonin on Insomnia Symptoms in Older Adults</brief_title>
  <official_title>Melatonin Randomized Trial for Insomnia in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nalaka Gooneratne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether melatonin tablets will increase the sleep of older adults
      with insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melatonin is a hormone secreted predominantly during the sleep period, suspected to have a
      strong link to the circadian sleep-wake cycle. Melatonin is also available in a pill form
      and, when administered during the day, tends to have a sedative effect. Clinical trials that
      have examined the nocturnal effects of melatonin have focused on patients of any age who have
      insomnia, regardless of their endogenous melatonin levels. Data indicate, however, that
      individuals with low endogenous melatonin levels may be more responsive to exogenous
      melatonin. Generally, melatonin levels decrease with age; therefore, older individuals with
      insomnia represent an ideal population in which to study the effects of exogenous melatonin
      on sleep. This study will provide older adults with insomnia melatonin tablets to determine
      whether the tablets will increase their sleep.

      Participation in this study will last 10 weeks and will comprise overnight visits at 2
      timepoints, the beginning of Week 1 and the end of Week 6. At study entry, participants will
      be admitted to the General Clinical Research Center for a 3-night stay, beginning with an
      overnight urine screen to confirm low melatonin levels. Participants will also be asked to
      begin a sleep diary documenting their sleep quality and quantity; the diary will be used
      throughout the study. During Night 1 at the clinic, participants will have urine samples
      collected throughout the night. Night 2 will be an adaptation night to allow participants to
      get used to their surroundings. On Night 3, participants will have sensors attached to their
      bodies and a polysomnograph machine will be used to measure their sleep efficiency.
      Participants with sleep efficiencies of 80% or higher will complete their study
      participation. Participants with sleep efficiencies less than 80% will be randomly assigned
      to one of three study treatments daily for 6 weeks: high-dose melatonin (4.0 mg), low-dose
      melatonin (0.4 mg), or placebo. Participants will have study visits at Weeks 1, 3, and 6 to
      monitor for adverse events. After 6 weeks, participants will have 2 more overnight clinic
      visits that will be identical to Nights 2 and 3 from the beginning of the study. Sleep
      questionnaires, cognitive tests, and psychomotor tests will be used to assess participants at
      the beginning of the study, after 6 weeks, and at the end of the study. One month after the
      end of the study, participants will have a follow-up visit to be reassessed for adverse
      events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Melatonin Level</measure>
    <time_frame>day 42</time_frame>
    <description>Pharmacokinetic analysis of maximum melatonin level</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 0.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 4.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 0.4 mg</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 4.0 mg</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of insomnia

          -  Low melatonin levels at study entry

        Exclusion Criteria:

          -  History of sleep apnea (temporary cessation of breathing during sleep)

          -  Diagnosis of restless legs syndrome

          -  Current alcohol or substance abuse

          -  Dementia

          -  Anemia

          -  Liver disease

          -  Leukemia or lymphoma

          -  Asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nalaka S. Gooneratne, MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012 May;52(4):437-45. doi: 10.1111/j.1600-079X.2011.00958.x. Epub 2012 Feb 21.</citation>
    <PMID>22348451</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2005</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>January 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2017</results_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Nalaka Gooneratne</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Aged</keyword>
  <keyword>Sleep</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Neurobehavioral Manifestations</keyword>
  <keyword>Circadian Rhythms</keyword>
  <keyword>Human</keyword>
  <keyword>Polysomnography</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A: Low Dose</title>
          <description>Melatonin 0.4 mg</description>
        </group>
        <group group_id="P2">
          <title>B: High Dose</title>
          <description>Melatonin 4.0 mg</description>
        </group>
        <group group_id="P3">
          <title>C: Control</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A: Low Dose</title>
          <description>Melatonin 0.4 mg</description>
        </group>
        <group group_id="B2">
          <title>B: High Dose</title>
          <description>Melatonin 4.0 mg</description>
        </group>
        <group group_id="B3">
          <title>C: Control</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="5.9"/>
                    <measurement group_id="B2" value="75.7" spread="4.7"/>
                    <measurement group_id="B3" value="75.1" spread="6.2"/>
                    <measurement group_id="B4" value="74.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Melatonin Level</title>
        <description>Pharmacokinetic analysis of maximum melatonin level</description>
        <time_frame>day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A: Low Dose</title>
            <description>Melatonin 0.4 mg</description>
          </group>
          <group group_id="O2">
            <title>B: High Dose</title>
            <description>Melatonin 4.0 mg</description>
          </group>
          <group group_id="O3">
            <title>C: Control</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Melatonin Level</title>
          <description>Pharmacokinetic analysis of maximum melatonin level</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405" spread="93"/>
                    <measurement group_id="O2" value="3999" spread="700"/>
                    <measurement group_id="O3" value="52" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3594</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>A: Low Dose</title>
          <description>Melatonin 0.4 mg</description>
        </group>
        <group group_id="E2">
          <title>B: High Dose</title>
          <description>Melatonin 4.0 mg</description>
        </group>
        <group group_id="E3">
          <title>C: Control</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study did not meet total recruitment targets</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nalaka Gooneratne</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2674083789</phone>
      <email>ngoonera@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

